Document Detail


Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant.
MedLine Citation:
PMID:  9556011     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the changes in acceleration time/right ventricular ejection time ratio (AT/RVET; indicative of changes in pulmonary artery pressure) calculated from Doppler ultrasound examinations performed before and 1, 6, and 12 h after the first and second doses of surfactant following the administration of each of three different surfactants during the acute phase of the respiratory distress syndrome. Maximum fractional inspired oxygen concentration (F(I,O2)) and peak inspiratory pressure (PIP) were recorded during each 4 h period from birth for the first 24 h and subsequently every 24 h until 72 h. Eighty-three infants were studied. Fifty patients weighing > 1 kg received Exosurf (n = 29) or ALEC (n = 21) and 33 weighing < or = 1 kg received Exosurf (n = 22) or Survanta (n = 11). The AT/RVET rose rapidly after administration of all three surfactants. There was no significant difference in the change in AT/RVET between those > 1 kg who received Exosurf and those who received ALEC (a synthetic surfactant). Similarly, there was no difference between those infants < or = 1 kg who received Exosurf and those who received Survanta. The F(I,O2) requirements, but not PIP, were lower in those infants who received Survanta at 12 and 20 h compared with those who received Exosurf. There was no significant difference in the F(I,O2) or PIP requirements between infants > 1 kg who received Exosurf compared with those who received ALEC. The rise in AT/RVET found in this study after administration of ALEC, Exosurf, or Survanta suggests that similar and rapid falls in pulmonary artery pressure occur after all three surfactant administrations, despite the difference in clinical response demonstrated between Exosurf and Survanta.
Authors:
A H Hamdan; N J Shaw
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pediatric pulmonology     Volume:  25     ISSN:  8755-6863     ISO Abbreviation:  Pediatr. Pulmonol.     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-06-09     Completed Date:  1998-06-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8510590     Medline TA:  Pediatr Pulmonol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  191-5     Citation Subset:  IM    
Affiliation:
Regional Neonatal Intensive Care Unit, Liverpool Women's Hospital, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acceleration
Biological Products*
Birth Weight
Blood Pressure / physiology*
Cardiac Output / physiology
Drug Combinations
Fatty Alcohols / therapeutic use
Humans
Infant, Newborn
Inhalation / physiology
Oxygen / administration & dosage,  blood
Phospholipids / therapeutic use
Phosphorylcholine*
Polyethylene Glycols / therapeutic use
Pressure
Pulmonary Artery / physiology*,  ultrasonography
Pulmonary Surfactants / classification,  therapeutic use*
Respiratory Distress Syndrome, Newborn / drug therapy*,  physiopathology,  ultrasonography
Time Factors
Ultrasonography, Doppler
Ventricular Function, Right / physiology
Chemical
Reg. No./Substance:
0/Biological Products; 0/Drug Combinations; 0/Fatty Alcohols; 0/Phospholipids; 0/Polyethylene Glycols; 0/Pulmonary Surfactants; 0/artificial lung expanding compound; 107-73-3/Phosphorylcholine; 108778-82-1/beractant; 7782-44-7/Oxygen; 99732-49-7/Exosurf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of neonatal surfactant therapy on lung function at school age in children born very preterm.
Next Document:  Rate of surfactant administration influences lung function and gas exchange in a surfactant-deficien...